Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Arena

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Human Mutation|January 8, 2013
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cellsDavide Zecchin, Sabrina Arena, Miriam Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind METCristina Basilico, Selma Pennacchietti, Elisa Vigna, et al.
Nature Communications|June 9, 2017
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistanceMoiez Ali, Erin Kaltenbrun, Gray R Anderson, et al.
Human Mutation|November 21, 2007
PIK3CA cancer mutations display gender and tissue specificity patternsSilvia Benvenuti, Milo Frattini, Sabrina Arena, et al.
Oncotarget|August 11, 2015
Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1Shuai Lu, Helga-Paula Török, Eike Gallmeier, et al.
Cancers|March 10, 2022
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective StudyAlessio Amatu, Gianluca Mauri, Federica Tosi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancerFederica Di Nicolantonio, Miriam Martini, Francesca Molinari, et al.
ACS Biomaterials Science & Engineering|August 26, 2025
A Deep Learning Approach for Tracking Colorectal Cancer-Derived Extracellular Vesicles in Colon and Lung ModelsGiulia Chiabotto, Bianca Dumontel, Luca Zilli, et al.
Cancer Biology & Therapy|January 17, 2004
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cellsKurtis E Bachman, Brian G Blair, Keith Brenner, et al.
Cancer Treatment Reviews|October 22, 2020
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunitiesGianluca Mauri, Viviana Gori, Erica Bonazzina, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Human Mutation|January 8, 2013
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cellsDavide Zecchin, Sabrina Arena, Miriam Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind METCristina Basilico, Selma Pennacchietti, Elisa Vigna, et al.
Nature Communications|June 9, 2017
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistanceMoiez Ali, Erin Kaltenbrun, Gray R Anderson, et al.
Human Mutation|November 21, 2007
PIK3CA cancer mutations display gender and tissue specificity patternsSilvia Benvenuti, Milo Frattini, Sabrina Arena, et al.
Oncotarget|August 11, 2015
Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1Shuai Lu, Helga-Paula Török, Eike Gallmeier, et al.
Cancers|March 10, 2022
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective StudyAlessio Amatu, Gianluca Mauri, Federica Tosi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancerFederica Di Nicolantonio, Miriam Martini, Francesca Molinari, et al.
ACS Biomaterials Science & Engineering|August 26, 2025
A Deep Learning Approach for Tracking Colorectal Cancer-Derived Extracellular Vesicles in Colon and Lung ModelsGiulia Chiabotto, Bianca Dumontel, Luca Zilli, et al.
Cancer Biology & Therapy|January 17, 2004
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cellsKurtis E Bachman, Brian G Blair, Keith Brenner, et al.
Cancer Treatment Reviews|October 22, 2020
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunitiesGianluca Mauri, Viviana Gori, Erica Bonazzina, et al.
Pageof 6